One study evaluated the selective MAT2A inhibitor IDE397 in combination with MTA‐cooperative PRMT5 inhibitors in MTAP‐deleted lung adenocarcinoma and pancreas cancer models H838 and BXPC3.21, 30. Here, MAT2A is linked to pancreatic neoplasm.